Through
4/26
Penn Medicine researchers have uncovered a liver-based signaling pathway that protects tumors by restraining anticancer immune cells.
Carl June accepted the 2024 Breakthrough Prize in Life Sciences at a Los Angeles ceremony, making him the sixth recipient from Penn.
Penn Medicine researchers have assessed the percentage of patients from minority health populations and reveal inequities in access to transformative CAR T cell therapy.
Penn Engineers have developed a novel method for manufacturing CAR T cells using lipid nanoparticles as delivery vehicles.
Gregory L. Beatty, an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center, and his team focus on improving immunotherapy for pancreatic cancer.
Early Penn Medicine trial results show that targeting two tumor-associated proteins in patients with recurrent glioblastoma may be a promising step toward developing cell therapies for solid tumors.
Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy.
New Penn Medicine research shows that following a single dose of a particular immunotherapy drug, CT scans “lit up” with metabolic changes in tumors that correlated with longer survival.
A new Penn Medicine analysis shows that the development of any type of second cancer is a rare occurrence, and some of the earliest patients have gone on to experience long-lasting remissions of a decade or more.
Researchers at Penn Medicine have developed an artificial intelligence tool to quickly analyze gene activities in medical images and provide single-cell insight into diseases in tissues and tissue microenvironments.
A 2020 study from the Perelman School of Medicine found that a blood test to screen for certain biomarkers associated with pancreatic cancer was 92% accurate in its ability to detect disease.
FULL STORY →
A clinical trial led by Stephen Bagley of the Perelman School of Medicine suggests that targeting two associated proteins with CAR T cell therapy could be a viable strategy for shrinking brain tumors.
FULL STORY →
Penn Medicine researchers like Nobel laureate Drew Weissman are leading efforts to develop a vaccine that prevents cancer, with remarks from Susan Domchek of the Basser Center for BRCA and Robert H. Vonderheide of the Abramson Cancer Center.
FULL STORY →
A trial led by Susan Domchek of the Perelman School of Medicine could use a preventive vaccine to protect people with a BRCA gene mutation from cancer.
FULL STORY →
Daiwei Zhang and Mingyao Li of the Perelman School of Medicine and colleagues have developed an AI tool called iStar that can automatically spot tumors and types of cancer that are difficult for clinicians to see or identify and can predict candidates for immunotherapy.
FULL STORY →
The Abramson Cancer Center is attempting to address one of the most common challenges cancer patients face: lack of transportation to critically important appointments. Robert Vonderheide and Carmen Guerra of the Perelman School of Medicine are quoted on the Ride Health initiative.
FULL STORY →